Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026)
Alnylam Pharmaceuticals (ALNY) Capital Expenditures (QoQ) (2009 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,681.27 Bn | 66,680.98 Bn | - |
| 2 | Nanobiotix | 1,942.19 Bn | 1,942.13 Bn | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - |
| 4 | BeOne Medicines | 475.46 Bn | 470.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 123.19 Bn | 115.94 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.44 Bn | 60.69 Bn | 3.31 Bn |
| 7 | Belite Bio | 63.20 Bn | 63.20 Bn | - |
| 8 | Argenx Se | 57.08 Bn | 51.90 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 38.11 Bn | 38.11 Bn | - |
| 10 | Alnylam Pharmaceuticals | 37.30 Bn | 34.29 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.53% |
| Dec 31, 2025 | 459.42% |
| Sep 30, 2025 | -195.56% |
| Jun 30, 2025 | 59.34% |
| Mar 31, 2025 | -1.36% |
| Dec 31, 2024 | -62.30% |
| Sep 30, 2024 | 2,145.80% |
| Jun 30, 2024 | -152.59% |
| Mar 31, 2024 | 105.20% |
| Dec 31, 2023 | -352.15% |
| Sep 30, 2023 | 7.37% |
| Jun 30, 2023 | 14.60% |
| Mar 31, 2023 | -78.92% |
| Dec 31, 2022 | 337.42% |
| Sep 30, 2022 | -272.89% |
| Jun 30, 2022 | -10.10% |
| Mar 31, 2022 | 143.68% |
| Dec 31, 2021 | -256.88% |
| Sep 30, 2021 | 23.31% |
| Jun 30, 2021 | 189.96% |